{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2014"],"condition":["Previously treated metastatic colorectal cancer"],"disease":["Previously Treated Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2629998"],"location":["Japan"],"study_start_month":["7"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of dose-escalation of Regorafenib for patients with previously treated metastatic colorectal cancer.","description":"Interventions: Regorafenib is administered orally once daily for 21 days followed by 7 days rest. The initial dose of regorafenib is 80mg/day, and dose-escalation to 120mg or 160mg/day should be considered every two weeks.\nPrimary outcome(s): Time to Treatment Failure\nStudy Design: Single arm Non-randomized","dates":{"creation":"2014-07-15"},"accession":"2629998","cross_references":{"Japan Primary Registries Network":["JPRN-UMIN000014661"]}}